Patents by Inventor Lindsay Bawden

Lindsay Bawden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection of histone modification in cell-free nucleosomes
    Publication number: 20070160989
    Abstract: This invention relates to the diagnosis of disease conditions, such as cancer and autoimmune disease, by the analysis of cell-free nucleosomes in samples from individuals. Methods of the invention may include contacting cell-free nucleosomes from a biological fluid sample obtained from the individual with an antibody that binds specifically with a modified histone protein. Binding of the antibody to the nucleosomes is indicative that the individual has the disease condition.
    Type: Application
    Filed: August 18, 2004
    Publication date: July 12, 2007
    Inventors: Lindsay Bawden, Elizabeth Bone, Alan Drummond, Lindsey Needham
  • IGF-II analogues
    Patent number: 5854025
    Abstract: Insulin-like Growth Factor II (IGF-II) analogues in which at least one of R37 and R38 is replaced with another amino acid residue, the most preferred being IGF-II R37Q R38Q, can readily be produced in E. coli, unlike natural IGF-II, which is cleaved on secretion. The analogues retain activity on the type I and type II IGF receptors but have lower affinity for the insulin receptor; they are therefore more specific in their action.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 29, 1998
    Assignee: British Biotech Pharmaceutical Limited
    Inventors: Richard Mark Edwards, Lindsay Bawden
  • IGF-II analogues
    Patent number: 5736363
    Abstract: Insulin-like Growth Factor II (IGF-II) analogues in which at least one of R37 and R38 is replaced with another amino add residue, the most preferred being IGF-II R37Q R38Q, can readily be produced in E. coli, unlike natural IGF-II, which is cleaved on secretion. The analogues retain activity on the type I and type II IGF receptors but have lower affinity for the insulin receptor; they are therefore more specific in their action.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: April 7, 1998
    Assignee: British Bio-technology Limited
    Inventors: Richard Mark Edwards, Lindsay Bawden